Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blanke, C. D.
Right arrow Articles by Participating investigators,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blanke, C. D.
Right arrow Articles by Participating investigators,
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:87-91, 2002
© 2002 European Society for Medical Oncology

A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer

C. D. Blanke1,+, J. Shultz2, J. Cox3, M. Modiano4, R. Isaacs5, B. Kasimis6, R. Schilsky7, J. Fleagle8, M. Moore9, N. Kemeny10, D. Carlin11, L. Hammershaimb11, D. Haller12 and Participating investigators§

1Oregon Health and Science University, Portland, OR; 2American Oncology Resources, Houston, TX; 3PRN Research, Dallas, TX; 4Arizona Clinical Research Center, Tucson, AZ; 5Hackensack Medical Center, Hackensack, NJ; 6East Orange VA Medical Center, East Orange, NJ; 7The University of Chicago, Chicago, IL; 8Boulder Valley Oncology, Boulder, CO; 9Georgia Cancer Specialists, Decatur, GA; 10Memorial Sloan Kettering Cancer Center, New York, NY; 11MedImmune Oncology, Inc., Gaithersburg, MD; 12University of Pennsylvania Cancer Center, Philadelphia, PA, USA

Received 12 September 2001; accepted 13 September 2001.

Background

Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC.

Patients and methods

Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity.

Results

A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41% and 28% on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77; Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon).

Conclusions

The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS.

Key words: biochemical modulation, colorectal cancer, 5-fluorouracil, leucovorin, randomized trial, trimetrexate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. R. Bertino
Modulation of 5-fluorouracil/leucovorin by trimetrexate--did it work?
Ann. Onc., January 19, 2002; 13(1): 10 - 11.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. J. A. Punt, H. J. Keizer, J. Douma, T. Skovsgaard, J. Schuller, E. W. Muller, C. H. H. Ten Napel, J. J. Croles, H. Lochs, J. Zhang, et al.
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
Ann. Onc., January 19, 2002; 13(1): 81 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. J. A. Punt, C. D. Blanke, J. Zhang, and L. Hammershaimb
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer
Ann. Onc., January 19, 2002; 13(1): 92 - 94.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.